Shell Asset Management Co. bought a new position in Agios Pharmaceuticals Inc (NASDAQ:AGIO) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 6,920 shares of the biopharmaceutical company’s stock, valued at approximately $534,000.

Several other institutional investors and hedge funds have also made changes to their positions in AGIO. Rockefeller Capital Management L.P. acquired a new position in shares of Agios Pharmaceuticals in the 3rd quarter worth approximately $134,000. Tiverton Asset Management LLC acquired a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $142,000. Strs Ohio acquired a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $179,000. MML Investors Services LLC acquired a new position in shares of Agios Pharmaceuticals in the 3rd quarter worth approximately $255,000. Finally, Piedmont Investment Advisors Inc. boosted its holdings in shares of Agios Pharmaceuticals by 342,300.0% in the 3rd quarter. Piedmont Investment Advisors Inc. now owns 3,424 shares of the biopharmaceutical company’s stock worth $264,000 after acquiring an additional 3,423 shares in the last quarter. 95.33% of the stock is currently owned by institutional investors and hedge funds.

AGIO stock opened at $53.17 on Friday. The firm has a market capitalization of $3.27 billion, a PE ratio of -7.88 and a beta of 2.18. Agios Pharmaceuticals Inc has a twelve month low of $51.37 and a twelve month high of $99.82.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.62) by ($0.01). The company had revenue of $15.20 million during the quarter, compared to analyst estimates of $22.72 million. Agios Pharmaceuticals had a negative net margin of 461.78% and a negative return on equity of 48.51%. The business’s revenue for the quarter was up 33.8% compared to the same quarter last year. During the same period last year, the company earned ($1.59) EPS. Sell-side analysts forecast that Agios Pharmaceuticals Inc will post -6.12 earnings per share for the current year.

AGIO has been the topic of several recent analyst reports. BidaskClub downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, October 6th. Cowen reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a report on Friday, November 2nd. Oppenheimer reaffirmed a “hold” rating on shares of Agios Pharmaceuticals in a report on Thursday, November 1st. Cann reaffirmed a “hold” rating on shares of Agios Pharmaceuticals in a report on Friday, November 16th. Finally, Leerink Swann started coverage on Agios Pharmaceuticals in a report on Monday, September 24th. They set a “market perform” rating and a $80.00 price objective on the stock. Six research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $96.27.

In other news, Director John Maraganore sold 13,555 shares of the stock in a transaction on Tuesday, September 11th. The stock was sold at an average price of $72.75, for a total value of $986,126.25. Following the transaction, the director now owns 38,609 shares of the company’s stock, valued at approximately $2,808,804.75. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Scott Biller sold 3,000 shares of the stock in a transaction on Monday, November 5th. The shares were sold at an average price of $69.69, for a total value of $209,070.00. Following the completion of the transaction, the insider now directly owns 53,932 shares in the company, valued at approximately $3,758,521.08. The disclosure for this sale can be found here. In the last three months, insiders sold 19,555 shares of company stock worth $1,404,566. 3.02% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “Shell Asset Management Co. Buys Shares of 6,920 Agios Pharmaceuticals Inc (AGIO)” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.dailypolitical.com/2018/12/08/shell-asset-management-co-buys-shares-of-6920-agios-pharmaceuticals-inc-agio.html.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Featured Story: Correction

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals Inc (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.